Jianzhijia Pharmaceutical Chain Group Co., Ltd.

SHSE:605266 Stock Report

Market Cap: CN¥4.1b

Jianzhijia Pharmaceutical Chain Group Future Growth

Future criteria checks 5/6

Jianzhijia Pharmaceutical Chain Group is forecast to grow earnings and revenue by 35.8% and 22.1% per annum respectively. EPS is expected to grow by 34.7% per annum. Return on equity is forecast to be 17% in 3 years.

Key information

35.8%

Earnings growth rate

34.7%

EPS growth rate

Consumer Retailing earnings growth45.0%
Revenue growth rate22.1%
Future return on equity17.0%
Analyst coverage

Low

Last updated26 Jun 2024

Recent future growth updates

No updates

Recent updates

Further Upside For Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Shares Could Introduce Price Risks After 33% Bounce

Nov 12
Further Upside For Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Shares Could Introduce Price Risks After 33% Bounce

We Think Jianzhijia Pharmaceutical Chain Group (SHSE:605266) Is Taking Some Risk With Its Debt

Oct 03
We Think Jianzhijia Pharmaceutical Chain Group (SHSE:605266) Is Taking Some Risk With Its Debt

What Is Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Share Price Doing?

Jul 16
What Is Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Share Price Doing?

Investors Don't See Light At End Of Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Tunnel And Push Stock Down 28%

Jun 19
Investors Don't See Light At End Of Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Tunnel And Push Stock Down 28%

Improved Earnings Required Before Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Shares Find Their Feet

Feb 27
Improved Earnings Required Before Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Shares Find Their Feet

Earnings and Revenue Growth Forecasts

SHSE:605266 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202615,719685N/A1,2521
12/31/202513,057562N/A1,1901
12/31/202410,768469N/A1,1501
9/30/20249,316237535818N/A
6/30/20249,228319452764N/A
3/31/20249,228390468793N/A
12/31/20239,0814147241,024N/A
9/30/20239,3054577991,078N/A
6/30/20238,8464421,1851,408N/A
3/31/20238,2314191,3541,551N/A
12/31/20227,5143744101,191N/A
9/30/20226,277300631,018N/A
6/30/20225,862268-177780N/A
3/31/20225,518267-280691N/A
12/31/20215,235301359744N/A
9/30/20214,947276506724N/A
6/30/20214,737262329536N/A
3/31/20214,578262179339N/A
12/31/20204,466251184317N/A
9/30/20204,213215186315N/A
12/31/20193,529168204338N/A
12/31/20182,76613489193N/A
12/31/20172,34795N/A206N/A
12/31/20162,05471N/A145N/A
12/31/20151,84418N/A-16N/A
12/31/20141,66717N/A66N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 605266's forecast earnings growth (35.8% per year) is above the savings rate (2.8%).

Earnings vs Market: 605266's earnings (35.8% per year) are forecast to grow faster than the CN market (25.8% per year).

High Growth Earnings: 605266's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 605266's revenue (22.1% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 605266's revenue (22.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 605266's Return on Equity is forecast to be low in 3 years time (17%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jianzhijia Pharmaceutical Chain Group Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Hui LiuChina Galaxy Securities Co., Ltd.
Kehan MengHaitong International Research Limited